Facilitating drug development using full-length transmembrane protein platforms

https://www.news-medical.net/whitepaper/20240724/Facilitating-drug-development-using-full-length-transmembrane-protein-platforms.aspx A crucial step in preclinical drug development is the confirmation of the novel therapeutic molecule's specific binding to the targeted protein. Transmembrane proteins (TPs) like ion channels, transporters, or receptors provide many targets for cancer and other diseases. They are complex, making producing those proteins in suitable amounts much more challenging than their soluble counterparts. This results in a bottleneck in the drug discovery workflow.